Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456344 | 1.00 | DNM1 (0.60) | DNM1MEN1KMT2ACA1CA2 | |
| Hydrochloric Acid SCHEMBL21197510 | 0.98 | DNM1 (0.58) | DNM1MEN1KMT2ACA1CA2 | |
| SCHEMBL13033269 | 0.87 | MEN1 (0.50) | DNM1MEN1KMT2ACA1CA2 | |
| SCHEMBL7159679 | 0.86 | MEN1 (0.67) | DNM1MEN1KMT2A | |
| SCHEMBL16316426 | 0.86 | MEN1 (0.58) | DNM1MEN1KMT2ALGALS1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30988427 | 0.85 | MEN1 (0.64) | DNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL25751510 | 0.85 | MEN1 (0.71) | DNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL16316310 | 0.83 | KMT2A (0.61) | DNM1MEN1KMT2ACA1CA2 | |
| SCHEMBL13584322 | 0.83 | DNM1 (0.57) | DNM1CA1CA2CA12CA9 | |
| SCHEMBL16384405 | 0.83 | MEN1 (0.68) | DNM1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | claimed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-8420820-B2 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | claimed |
| JP-2012500285-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | claimed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| US-4326067-A | FROM OXAZOLINE WITH AN AMINE | THE DOW CHEMICAL COMPANY (US) | 1982-04-20 | — | — | US | claimed |
| CN-119841829-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2025-04-18 | — | — | CN | disclosed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023078230-A1 | ANTIBODY-DRUG CONJUGATE INTERMEDIATE COMPRISING SN38 AND PREPARATION METHOD THEREFOR | 烟台迈百瑞国际生物医药股份有限公司 | 2023-05-11 | — | — | WO | disclosed |
| EP-0090063-B1 | PROCESS FOR MAKING N-(2-AMINOETHYL)AMIDES FROM OXAZOLINES AND AMINES | THE DOW CHEMICAL COMPANY (US) | 1985-09-11 | — | — | EP | disclosed |
| US-4515923-A | HYDROLYSIS OF POLYISOCYANATES | BAYER AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | disclosed |
| EP-0097298-A2 | Polyamines, process for producing polyamines and their use in the production of polyurethanes | BAYER AG (DE) | 1984-01-04 | — | — | EP | disclosed |
| EP-0097299-A2 | Polyamines, process for producing polyamines and their use in the production of polyurethanes | BAYER AG (DE) | 1984-01-04 | — | — | EP | disclosed |
| EP-0090063-A1 | Process for making N-(2-aminoethyl)amides from oxazolines and amines | THE DOW CHEMICAL COMPANY (US) | 1983-10-05 | — | — | EP | disclosed |
| US-4326067-A | FROM OXAZOLINE WITH AN AMINE | THE DOW CHEMICAL COMPANY (US) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MKI67, CCNT1, CCNI | DNM1 1159/4885MEN1 835/4885KMT2A 1652/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | DNM1 1515/4885MEN1 1620/4885KMT2A 438/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | DNM1 2837/4885MEN1 887/4885KMT2A 242/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | DNM1 4341/4885MEN1 1615/4885KMT2A 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.